A recent research published in the Clinical Gastroenterology and Hepatology Journal sheds light on the rapidly growing prevalence of Eosinophilic Oesophagitis (EoE). 

EoE is a chronic immune-mediated condition where eosinophils, a type of white blood cell, build up in the lining of the oesophagus, leading to inflammation and damage. This can cause symptoms such as difficulty swallowing, food impaction, and chest pain. Left untreated, EoE can result in oesophageal narrowing and other complications, significantly impacting quality of life.

This condition imposes financial, emotional, and social challenges on individuals, families, and carers while also straining healthcare systems due to its under-recognition and inadequate treatment, often leading to complications. 

Stories of people who live with EoE 

About the study

Researchers utilised large administrative databases, such as MarketScan and Medicare, along with International Classification of Disease (ICD) codes to calculate the annual prevalence of EoE.

They also provided age- and sex-stratified estimates, standardised to the U.S. population. Healthcare utilisation, including the use of medications and endoscopic procedures, was quantified, and the annual costs associated with EoE were estimated.

Results

The study found a significant rise in EoE cases, with a five-fold increase in prevalence since 2009. In 2022, MarketScan recorded 163.08 cases per 100,000, and Medicare reported 64.83 cases per 100,000 in 2017. Prevalence was higher among males and peaked between ages 40 and 44. When adjusted to the U.S. population, this equates to an estimated 472,380 cases. Total EoE-related healthcare costs for 2024 were projected at $1.32 billion.

When adjusted to the U.S. population, the overall prevalence is approximately 1 in 700. The annual healthcare costs linked to EoE are projected at $1.3 billion in 2024, highlighting a significant economic impact.

Conclusions

With annual costs of $1.3 billion, EoE poses a significant economic challenge, requiring optimised care strategies. The increasing prevalence of EoE highlights the need for better awareness, early diagnosis, and targeted interventions.

Read the full publication

Authors: Hannah L. Thel1 Chelsea Anderson2 Angela Z. Xue1 Elisabeth T. Jensen2,3 Evan S. Dellon

---

Read similar news:

Eosinophilic Diseases Research: Past, Present and Future

New Potential Tool to Evaluate EoE Severity

Access to Dupixent (Dupilumab) Treatment in the UK Explained

Understanding the Disease Burden of Eosinophilic Granulomatosis with Polyangiitis (EGPA)